Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for reducing adverse drug reactions during MDR-TB treatment in Tanzania
PACTR202007736854169Phase 2Completed
- Sponsor
- Stellah Mpagama
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of acetylcysteine in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Stellah Mpagama. Primary endpoint: Development of clinical or laboratory-based adverse events. Started Jun 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on PACTR202007736854169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007736854169.